NCT03385668View on ClinicalTrials.gov

Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

July 24, 2020

Study Completion Date

July 24, 2020

Conditions
Pulmonary Fibrosis
Interventions
DRUG

Pirfenidone

Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).

Trial Locations (1)

75014

Cochin Hospital, Paris

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03385668 - Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies | Biotech Hunter | Biotech Hunter